|
WO2020252005A1
|
|
Methods and compositions for altering senescence associated secretory phenotype
|
|
WO2020214993A1
|
|
25-hydroxycholesterol (25hc), cryab aggregation inhibitor, is a novel senolytic
|
|
WO2020163510A1
|
|
Methods of inducing autophagy using coumarin derivatives and related compounds
|
|
WO2020123409A1
|
|
S3qels to protect against intestinal permeability
|
|
WO2019231929A1
|
|
Gene-drive in dna viruses
|
|
US2019382451A1
|
|
Zika as a cell penetrating peptide for delivery to the brain
|
|
US2021094900A1
|
|
Synthesis of 3-hydroxybutyryl 3-hydroxybutyrate and related compounds
|
|
WO2019070407A1
|
|
Biomarker for senescent cells
|
|
WO2019018683A1
|
|
S-enantiomers of beta-hydroxybutyrate and butanediol and methods for using same
|
|
EP3615029A2
|
|
Formulations for extending lifespan and healthspan
|
|
US2018015051A1
|
|
Modulators of alpha-dicarbonyl detoxification and their use for the treatment of diabetic pathologies
|
|
KR20190006515A
|
|
Compounds that promote normal processing of APP
|
|
US2017112804A1
|
|
Lipoic acid and derivatives thereof for the treatment of cystinuria
|
|
US2018268940A1
|
|
Compositions and methods for specific biological cognitive functions in neurodegenerative diseases
|
|
AU2016315653A1
|
|
Rapamycin analogs showing improved mTORC1 specificity
|
|
US2017042129A1
|
|
Transgenic mouse for determining the role of senescent cells in cancer
|
|
US2017027139A1
|
|
Transgenic mouse having a transgene that converts a prodrug into a cytotoxic compound in senescent cells
|
|
US2017348266A1
|
|
Inhibition of proline catabolism for the treatment of cancer and other therapeutic applications
|
|
AU2014216390A1
|
|
Hydantoins that modulate BACE-mediated APP processing
|
|
AU2012290116A1
|
|
Tropinol esters and related compounds to promote normal processing of APP
|
